It is currently recommended to estimate the individual PSA-based odds of PCa to address the rescreening interval, active surveillance, and biopsy referral, seeking for a reduction of harms associated with the procedure invasiveness, overdiagnosis, and overtreatment of low-risk disease. Here, KLK3 is linked to posterior cortical atrophy.